You are here
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
F. Roila, J. Herrstedt, M. Aapro, R. J. Gralla, L.H. Einhorn, E. Ballatori, E. Bria, R.A. Clark-Snow, B. T. Espersen, P. Feyer, S.M. Grunberg, P.J. Hesketh, K. Jordan, M.G. Kris, E. Maranzano, A. Molassiotis, G. Morrow, I. Olver, B.L. Rapoport
Annals of Oncology 2010; 21(Suppl 5): v232–v243
Despite the relevant progress achieved in the last 20 years, vomiting and, especially, nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In the late 1990s several professional organizations published recommendations on the optimal antiemetic prophylaxis in patients submitted to chemotherapy and radiotherapy.
Subsequently, due to the emergence of new findings and new antiemetic agents since the first recommendations from 1997, representatives from several oncology societies met in Perugia, Italy, in 2004 and updated the antiemetic guidelines. On 20–21 June 2009 the European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) organized the third Consensus Conference on antiemetics in Perugia. The results of this Conference are reported in this paper.